The authors report a case o f a male patient from Bacabal, MA with diffuse cutaneous leishmaniasis (DCL) Diffuse cutaneous leishmaniasis (DCL) is a rare form of cutaneous leishmaniasis in which cellular immunity to leishmania antigens is absent and which shows a poor response to antileishmanial agents. According to Silva12, who originally described the disease in Brazil, initial lesions are macular, papular or nodular containing abundant parasites. Regional lymphadenopathy and mucosal lesions are uncommon and visceral lesions unreported5.
Diffuse cutaneous leishmaniasis (DCL) is a rare form of cutaneous leishmaniasis in which cellular immunity to leishmania antigens is absent and which shows a poor response to antileishmanial agents. According to Silva12, who originally described the disease in Brazil, initial lesions are macular, papular or nodular containing abundant parasites. Regional lymphadenopathy and mucosal lesions are uncommon and visceral lesions unreported5.
The disease begins as a nodule, to spread locally and distally to the rest of the skin. Although the Montenegro skin test is negative, ind icatin g a lack o f cellu lar imm unity to leishmania antigens, DCL patients do respond to unrelated skin test antigens such as PPD and candidin3 5.
Bryceson4 used various treatment regimens o f drug in 24 DCL patients, pentam idine m e s y la te (4 m g / k g / d a ily ) r e s u lte d in improvement in all 24 patients, but relapsed. Pentostam (lOmg/sbV/kg for 5-30 days) resulted in initial improvement. One of 6 patients was cured with primaquine 30mg per day for 2 months, and did not relapse over 14 months. This case probably shows that the rare case of diffuse disease with only one lesion may self heal. Amphotericin B (lmg/kg/for about 2 months) was used in 4 patients. In Peru, pentostam (20mg/sbV/day for 60 days) resulted in improvement but not cure7.
In Brazil, the drug of choice for the treatment of mucocutaneous and DCL is the pentavalent antimonial (glucantime®)10 13. 
CASE REPORT
RNPS, 31 years old, man, landworker, from the state of Maranhão, northeast of Brazil, had DCL caused by Leishmania amazonensis, for at least nine years. During the last three years, he was submitted to various therapy schedules (glucantime®, amphotericin B, g lu c a n tim e ® p lu s g a m m a -in te r fe r o n ),
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Before the administration of pentamidine iseth io n ate in Sep tem ber 1991 a clin icallaboratorial evaluation was performed. At that occasion the patient had active lesions with small nodules and erythematous tubercules associated with scars on his face, chest and abdomen. A total of 168 active lesions were found plaques and erythematous tubercules with ulcerations covered with crusts were observed on his hands and feet. Red and white blood cells counts, urea, creatinine, alkaline p h o s p h a ta s e , AST, ALAT w e re w ith o u t alteration s. The b lood glu cose level was 77mg/dl.
Pentamidine isethionate was administered in a dose of 4mg/kg on alternate days for 20 IM applications. W hen glucose alteration appeared (123mg/dl), the drug was dismissed temporarily. After 3 months, pentamidine was reintroduced in the same dose regimen for 10 applications. At the end of these series glucose blood level was lOOmg/dl. Another regimen of the drug was done three months later, and the same evolution .occurred. The total dose was 8.4g of pentamidine isethionate. In this period glucose blood levels varied between 80 to lOOmg/dl in the last three regimens. The patient was discharged with improvement, but still showing crusts on the lower limbs and scars throughout the body. The Montenegro skin test remained negative.
He returned to the hospital a month after discharge (October 1992), with weight loss of, 10kg, polyd ypsia, polyuria, xerostom ia, weakness and relapse o f the lesions of the lower limbs (ulcerations with crusts and secondary infection). The glucose blood level was 420mg/dl, glucose and ketonic bodies were present on the urinalysis. He needed insulin control for 22 days, when glucose levels becam e normal, persisting some active lesions on his legs. He later improved after therapy with aminosidine.
DISCUSSION
Bryceson2 3 treated 33 patients with diffuse cutaneous leishmaniasis (DCL) with a variety of agents. Pentamidine mesylate gave the best results, with initial improvement in all patients and long term cure in seven. He concluded that pentam idine given w eekly or biw eekly was the best available therapy for this disease although its toxic effects limited the dosage and frequency of injections. The side effects included collapse (presumably due to the drug e n te r in g a v e in ), p ro fo u n d w e a k n e s s , anorexia, nausea, vomiting, abdominal pain, glycosuria, altered glucose tolerance test and diabetes.
Although clinical experience appears to be la c k in g , s e v e r a l a u th o rs re c o m m e n d e d pentam idine for the treatm ent o f cases of visceral leishmaniasis and mucocutaneous leishmaniasis that have been unresponsive to antimonial agents6 9. Jh a8 has reported to have s u c e s s fu lly tr e a te d 81 o f 82 c a s e s o f pentavalent antimony-resistant kalazar with pentamidine mesylate in North Bihar, India.
T h e r e is a s u g g e s t i o n t h a t t h e d im eth a n esu lfo n a te salt (m e sy la te ) o f pentamidine may be more diabetogenic than isethionate2 4 6 8. The mechanism of the d ia b e to g e n ic e f f e c t o f p e n ta m id in e is considered to be similar to that of streptozocin, causing an early citolytic release of insulin and hypoglicemia, followed by insulin deprivation and diabetes mellitus because of a toxic effect on the B-cells of the pancreas. Approximately 5% of the treated patients will develop glucose in toleran ce or in su lin -d ep en d en t d iabetes during pentamidine therapy, some having antecedent hypoglicemia1 n.
Only this patient out of five cases of DCL in M ara n h ã o tr e a te d w ith is e t h io n a te o f pentamidine developed diabetes mellitus, being the first report o f DCL in Brazil, treated w ith th is d ru g th a t d e v e lo p e d d ia b e te s mellitus, without previous renal damage. Fortunately insulin independent, but control of glucose on the blood, are being done every three months. 
RESUMO

